Rankings
▼
Calendar
ALNY FY 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$43B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$844M
+71.3% YoY
Gross Profit
$704M
83.4% margin
Operating Income
-$709M
-83.9% margin
Net Income
-$853M
-101.0% margin
EPS (Diluted)
$-7.20
Cash Flow
Operating Cash Flow
-$642M
Free Cash Flow
-$718M
Stock-Based Comp.
$166M
Balance Sheet
Total Assets
$3.6B
Total Liabilities
$3.1B
Stockholders' Equity
$588M
Cash & Equivalents
$820M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$844M
$493M
+71.3%
Gross Profit
$704M
$415M
+69.8%
Operating Income
-$709M
-$828M
+14.5%
Net Income
-$853M
-$858M
+0.6%
← Q4 2020
All Quarters
Q1 2021 →